GENIUS SPORTS LTD (GENI) Fundamental Analysis & Valuation

NYSE:GENI • GG00BMF1JR16

Current stock price

4.47 USD
+0.12 (+2.76%)
At close:
4.47 USD
0 (0%)
After Hours:

This GENI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. GENI Profitability Analysis

1.1 Basic Checks

  • GENI had negative earnings in the past year.
  • GENI had a positive operating cash flow in the past year.
  • In the past 5 years GENI always reported negative net income.
  • In multiple years GENI reported negative operating cash flow during the last 5 years.
GENI Yearly Net Income VS EBIT VS OCF VS FCFGENI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 -200M -400M -600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -9.87%, GENI is doing worse than 85.71% of the companies in the same industry.
  • The Return On Equity of GENI (-15.40%) is worse than 60.32% of its industry peers.
Industry RankSector Rank
ROA -9.87%
ROE -15.4%
ROIC N/A
ROA(3y)-9.62%
ROA(5y)-24.09%
ROE(3y)-13.78%
ROE(5y)-31.67%
ROIC(3y)N/A
ROIC(5y)N/A
GENI Yearly ROA, ROE, ROICGENI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • GENI has a Gross Margin of 22.98%. This is amonst the worse of the industry: GENI underperforms 83.33% of its industry peers.
  • GENI's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for GENI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y200.08%
GM growth 5YN/A
GENI Yearly Profit, Operating, Gross MarginsGENI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. GENI Health Analysis

2.1 Basic Checks

  • GENI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for GENI has been increased compared to 1 year ago.
  • The number of shares outstanding for GENI has been increased compared to 5 years ago.
  • GENI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GENI Yearly Shares OutstandingGENI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
GENI Yearly Total Debt VS Total AssetsGENI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 0.60, we must say that GENI is in the distress zone and has some risk of bankruptcy.
  • GENI's Altman-Z score of 0.60 is on the low side compared to the rest of the industry. GENI is outperformed by 74.60% of its industry peers.
  • GENI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 0.6
ROIC/WACCN/A
WACC9.6%
GENI Yearly LT Debt VS Equity VS FCFGENI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • GENI has a Current Ratio of 1.56. This is a normal value and indicates that GENI is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Current ratio value of 1.56, GENI is doing good in the industry, outperforming 72.22% of the companies in the same industry.
  • A Quick Ratio of 1.56 indicates that GENI should not have too much problems paying its short term obligations.
  • GENI has a better Quick ratio (1.56) than 76.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 1.56
GENI Yearly Current Assets VS Current LiabilitesGENI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. GENI Growth Analysis

3.1 Past

  • The earnings per share for GENI have decreased strongly by -59.26% in the last year.
  • GENI shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.04%.
  • Measured over the past years, GENI shows a very strong growth in Revenue. The Revenue has been growing by 25.22% on average per year.
EPS 1Y (TTM)-59.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)31.04%
Revenue growth 3Y25.22%
Revenue growth 5YN/A
Sales Q2Q%37.01%

3.2 Future

  • Based on estimates for the next years, GENI will show a very strong growth in Earnings Per Share. The EPS will grow by 50.26% on average per year.
  • GENI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.02% yearly.
EPS Next Y110.59%
EPS Next 2Y67.57%
EPS Next 3Y50.26%
EPS Next 5YN/A
Revenue Next Year22.71%
Revenue Next 2Y21.41%
Revenue Next 3Y18.02%
Revenue Next 5Y20.02%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GENI Yearly Revenue VS EstimatesGENI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B
GENI Yearly EPS VS EstimatesGENI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

2

4. GENI Valuation Analysis

4.1 Price/Earnings Ratio

  • GENI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 98.19, GENI can be considered very expensive at the moment.
  • 65.08% of the companies in the same industry are cheaper than GENI, based on the Price/Forward Earnings ratio.
  • GENI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.24.
Industry RankSector Rank
PE N/A
Fwd PE 98.19
GENI Price Earnings VS Forward Price EarningsGENI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, GENI is valued a bit more expensive than 63.49% of the companies in the same industry.
Industry RankSector Rank
P/FCF 209.04
EV/EBITDA N/A
GENI Per share dataGENI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • GENI's earnings are expected to grow with 50.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y67.57%
EPS Next 3Y50.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GENI Dividend Analysis

5.1 Amount

  • GENI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GENI Fundamentals: All Metrics, Ratios and Statistics

GENIUS SPORTS LTD

NYSE:GENI (4/24/2026, 8:04:00 PM)

After market: 4.47 0 (0%)

4.47

+0.12 (+2.76%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)03-04
Earnings (Next)05-07
Inst Owners95.03%
Inst Owner Change-0.17%
Ins Owners9.48%
Ins Owner Change0.74%
Market Cap1.15B
Revenue(TTM)669.49M
Net Income(TTM)-111.58M
Analysts82.4
Price Target11.73 (162.42%)
Short Float %6.57%
Short Ratio2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1558.58%
Min EPS beat(2)-2756.23%
Max EPS beat(2)-360.92%
EPS beat(4)1
Avg EPS beat(4)-1071.76%
Min EPS beat(4)-2756.23%
Max EPS beat(4)16.89%
EPS beat(8)2
Avg EPS beat(8)-619.22%
EPS beat(12)2
Avg EPS beat(12)-425.95%
EPS beat(16)4
Avg EPS beat(16)-342.27%
Revenue beat(2)2
Avg Revenue beat(2)2.24%
Min Revenue beat(2)0.65%
Max Revenue beat(2)3.82%
Revenue beat(4)2
Avg Revenue beat(4)0.18%
Min Revenue beat(4)-2.01%
Max Revenue beat(4)3.82%
Revenue beat(8)3
Avg Revenue beat(8)-0.31%
Revenue beat(12)5
Avg Revenue beat(12)0.43%
Revenue beat(16)7
Avg Revenue beat(16)1.18%
PT rev (1m)-8.2%
PT rev (3m)-26.31%
EPS NQ rev (1m)-8.47%
EPS NQ rev (3m)-90.85%
EPS NY rev (1m)-67.39%
EPS NY rev (3m)-47.82%
Revenue NQ rev (1m)-0.68%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)-5.77%
Revenue NY rev (3m)3.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 98.19
P/S 1.72
P/FCF 209.04
P/OCF 13.31
P/B 1.59
P/tB 4.75
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)0.05
Fwd EY1.02%
FCF(TTM)0.02
FCFY0.48%
OCF(TTM)0.34
OCFY7.51%
SpS2.6
BVpS2.82
TBVpS0.94
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -9.87%
ROE -15.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.98%
FCFM 0.82%
ROA(3y)-9.62%
ROA(5y)-24.09%
ROE(3y)-13.78%
ROE(5y)-31.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y200.08%
GM growth 5YN/A
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 114.71%
Cap/Sales 12.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.56
Quick Ratio 1.56
Altman-Z 0.6
F-Score4
WACC9.6%
ROIC/WACCN/A
Cap/Depr(3y)88.94%
Cap/Depr(5y)78.48%
Cap/Sales(3y)12.19%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y110.59%
EPS Next 2Y67.57%
EPS Next 3Y50.26%
EPS Next 5YN/A
Revenue 1Y (TTM)31.04%
Revenue growth 3Y25.22%
Revenue growth 5YN/A
Sales Q2Q%37.01%
Revenue Next Year22.71%
Revenue Next 2Y21.41%
Revenue Next 3Y18.02%
Revenue Next 5Y20.02%
EBIT growth 1Y-151.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year279.58%
EBIT Next 3Y79.11%
EBIT Next 5Y58.03%
FCF growth 1Y-68.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.54%
OCF growth 3YN/A
OCF growth 5YN/A

GENIUS SPORTS LTD / GENI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GENIUS SPORTS LTD (GENI) stock?

ChartMill assigns a fundamental rating of 4 / 10 to GENI.


What is the valuation status for GENI stock?

ChartMill assigns a valuation rating of 2 / 10 to GENIUS SPORTS LTD (GENI). This can be considered as Overvalued.


Can you provide the profitability details for GENIUS SPORTS LTD?

GENIUS SPORTS LTD (GENI) has a profitability rating of 1 / 10.


How financially healthy is GENIUS SPORTS LTD?

The financial health rating of GENIUS SPORTS LTD (GENI) is 5 / 10.